Microbiome Modulator

Microbiota Accessible Carbohydrates

Fermentable non-digestible carbohydrates

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

10-25

watchEffect Window

GI effects can emerge within days-weeks. Metabolic markers often require weeks-months.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Microbiota-accessible carbohydrates are fermentable fibers that nourish gut microbes.

They can improve constipation and selected metabolic markers when dosed consistently and titrated for tolerance. Rapid dose escalation commonly increases GI symptoms.

Fermentable fibers feed gut microbes and produce SCFAs, supporting metabolic and gastrointestinal outcomes.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Glycemic-control support in prediabetes/type 2 diabetes
  • Bowel-function and constipation symptom improvement

Secondary Outcomes

  • Microbiota composition modulation
  • SCFA-related gut-metabolic pathway support

Safety

Contraindications and Interactions

Contraindications

  • Bowel obstruction/stricture risk
  • Severe uncontrolled GI disease without supervision
  • Replacement of indicated diabetes/GI medical care

Side effects

  • Gas/bloating
  • Abdominal discomfort/cramping
  • Stool-pattern changes during titration

Interactions

  • Possible oral-medication absorption timing effects
  • Potential additive glycemic effects with diabetes medications
  • Multi-fiber stacking can intensify GI side effects

Avoid if

  • Inability to titrate slowly
  • Severe FODMAP sensitivity without guidance
  • Inability to monitor endpoint response

Evidence

Study-level References

microbiota-accessible-carbohydrates-SRC-001GRADE-assessed systematic review and dose-response meta-analysis
Sourceopen_in_new

Wang L, et al. Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose-response meta-analysis of 33 randomized controlled trials. J Transl Med. 2019;17(1):410. doi:10.1186/s12967-019-02159-0. PMID:31805963

Population: Prediabetes and type 2 diabetes trial populations

Dose protocol: Inulin-type fructans, variable doses and durations

Key findings: Significant glycemic-control improvement

Notes: Heterogeneous interventions and baseline metabolic states

Paper content

Significant glycemic-control improvement

microbiota-accessible-carbohydrates-SRC-002Systematic review and meta-analysis
Sourceopen_in_new

Xiong K, et al. Effects of resistant starch on glycaemic control: a systematic review and meta-analysis. Br J Nutr. 2021;125(11):1260-1269. doi:10.1017/S0007114520003700. PMID:32959735

Population: RCTs of resistant starch interventions

Dose protocol: Variable resistant starch types/doses

Key findings: Overall favorable effects on glycemic outcomes

Notes: Substantial heterogeneity and variable intervention quality

Paper content

Overall favorable effects on glycemic outcomes

microbiota-accessible-carbohydrates-SRC-003Double-blind randomized placebo-controlled trial
Sourceopen_in_new

Lai H, et al. Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial. Gut Microbes. 2023;15(1):2197837. doi:10.1080/19490976.2023.2197837. PMID:37078654

Population: Adults with functional constipation

Dose protocol: Dietary-fiber intervention versus control conditions

Key findings: Improved constipation outcomes with microbiota shifts

Notes: Mixed intervention arms can complicate fiber-only attribution

Paper content

Improved constipation outcomes with microbiota shifts

microbiota-accessible-carbohydrates-SRC-004Systematic review and network meta-analysis
Sourceopen_in_new

Juhász AE, et al. Galactomannans are the most effective soluble dietary fibers in type 2 diabetes: a systematic review and network meta-analysis. Am J Clin Nutr. 2023;117(2):266-277. doi:10.1016/j.ajcnut.2022.12.015. PMID:36811560

Population: Adults with type 2 diabetes across soluble-fiber RCTs

Dose protocol: Multiple soluble-fiber classes

Key findings: Differential efficacy across fiber classes, highlighting subtype selection importance

Notes: Indirect comparisons and class-level heterogeneity

Paper content

Differential efficacy across fiber classes, highlighting subtype selection importance

microbiota-accessible-carbohydrates-SRC-005Pilot randomized controlled trial
Sourceopen_in_new

Mitchell CM et al. 2021. "Prebiotic Inulin Supplementation and Peripheral Insulin Sensitivity in adults at Elevated Risk for Type 2 Diabetes: A Pilot Randomized Controlled Trial." Nutrients. 13(9):3235. PMID: 34579112. DOI: 10.3390/nu13093235.

Population: Adults at elevated risk for type 2 diabetes.

Dose protocol: Inulin 10 g/day versus maltodextrin placebo for 6 weeks.

Key findings: Improved fasting insulin, HOMA-IR, and Bifidobacteria abundance, but did not improve peripheral insulin sensitivity.

Notes: Small pilot RCT that usefully tempers overbroad metabolic claims.

Paper content

Six weeks of 10 g/day inulin improved fasting insulin, HOMA-IR, and Bifidobacteria abundance in adults at elevated diabetes risk, but did not improve peripheral insulin sensitivity in this small pilot trial.

Guides

Setup

Help